Background: Dystrophin deficiency sensitizes skeletal muscle of mice to eccentric contraction (ECC)-induced strength loss. ECC protocols distinguish dystrophin-deficient from healthy, wild type muscle, and test the efficacy of therapeutics for Duchenne muscular dystrophy (DMD). However, given the large lab-to-lab variability in ECCinduced strength loss of dystrophin-deficient mouse skeletal muscle (10-95%), mechanical factors of the contraction likely impact the degree of loss. Therefore, the purpose of this study was to evaluate the extent to which mechanical variables impact sensitivity of dystrophin-deficient mouse skeletal muscle to ECC.
Introduction
Mutation in the DMD gene can detrimentally affect the expression and function of its product dystrophin [1] , a protein that stabilizes the sarcolemma during contraction by linking the extracellular matrix to the intracellular cytoskeleton [2] . Lack of dystrophin renders skeletal muscle susceptible to injury [3] , particularly eccentric contraction (ECC)-induced strength loss [4] [5] [6] . Such loss of strength in the mdx mouse model of Duchenne muscular dystrophy (DMD) is associated with cytosolic calcium influx [7] , generation of reactive oxygen species (ROS) [8] and ultimately disruption of the mechanisms responsible for activating, generating, and transmitting force. ECC-induced strength loss in skeletal muscle of mdx mice can be partially attenuated by treating with antioxidants [9, 10] , increasing sarco-endoplasmic reticulum (SR) calcium transport ATPase (SERCA1a) expression [11] or inhibiting resting-muscle SR calcium leak through ryanodine receptor (RyR1) calcium release channels [12] .
Mechanical factors of the ECC that cause strength loss in wild type (WT) skeletal muscle include work performed by the muscle [13] , initial length of the muscle, amplitude of the length change [14] , and maximal muscle tension [15] during the ECC, with the latter being measured as the ratio of maximal eccentric to isometric force (ECC:ISO). We recently reported that in mdx muscle, fiber types and variable expression of utrophin, cytoplasmic actins, and SERCA1-but not ECC: ISO-predict ECC-induced strength loss [16] . Call et al. [17] and Baumann et al. [18] also revealed that loss of sarcolemmal excitability due to depolarization of mdx fibers following in vivo ECC is a primary mechanism of strength loss and is distinctly different from WT. Such results suggest that different mechanisms govern the initiation of ECC-induced strength loss in dystrophindeficient and WT skeletal muscle, yet it remains to be seen whether the mechanical factors of an ECC that influence the extent of strength loss are the same in mdx as in WT.
While ECC protocols vary across laboratories in the number of contractions, time between contractions, magnitude of length change, velocity of lengthening, and duration of the contraction (Table 1) , they all robustly differentiate mdx skeletal muscle from WT [5, 6, 16, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . However, published force losses in mdx extensor digitorum longus (EDL) muscle range from 10 to 95% (Table 1) indicating that protocol variables impact the severity of force loss. Therefore, we investigated the extent to which each mechanical variable of an ECC affects force loss in mdx skeletal muscle. We determined that a high stimulation frequency is required to induce loss of strength and that the magnitude of the work, length change, and stimulation duration of an ECC primarily dictate the extent of ECC-induced strength loss in mdx muscle. We then utilized this knowledge to show that altering the magnitude of ECC length change can better reveal therapeutic efficacy, here in the case of an antioxidant and calcium modulators.
Materials and methods

Experimental mice
Three-month-old male mdx mice (C57BL/10ScSn-DMDmdx/J) were generated using founders purchased from Jackson Laboratory (Bar Harbor, ME, USA). All mice were housed in groups of 3-4 per cage on a 14/10h light/dark cycle with food and water provided ad libitum.
Study design
Ex vivo ECC protocols were designed to determine which mechanical factors were most influential in initiating ECC-induced force loss. To determine the stimulation frequencies required to manipulate ECC:ISO, we first completed a force-frequency analysis of isolated EDL muscle. Because ECC:ISO was determined to be the dominant factor initiating ECC-induced force loss in WT skeletal muscle (19) , we manipulated ECC:ISO by using a passive lengthening (no stimulation, 0 Hz), a stimulation frequency that elicited force half-way between twitch and maximal tetanic forces, and a stimulation frequency that elicited maximal tetanic force. Each stimulation frequency (0, 35, 120 Hz), muscle length change (5, 10, 20 , and 30%, L o ) and contraction velocity (0.125, 0.25, 0.5, 1.0, 2.0, and 3.0 L o /s) were tested for a total of 51 ECC protocols (Additional file 1: Figure S1 ). Each protocol was designed based on those tested in WT muscle [15] , keeping within physiological limitations and using the dual-mode lever system (300B-LR; Aurora Scientific Inc., Aurora, ON, Canada). The study's primary outcome was change in maximal isometric force and changes in maximal tetanic rates of contraction and relaxation following ECC. To prevent a metabolic influence on the ECC protocol, we only used 10 ECC separated by three min.
To determine which mechanical factors contribute to torque loss of dystrophin-deficient skeletal muscle in vivo, we completed ECC of the anterior crural muscles (tibialis anterior, EDL and extensor hallucis longus) where ECC:ISO (0.52-2.37), degree of ankle rotation (0-40°), contraction velocity (0-2000°/s), and contraction duration (0-320 ms) were manipulated in mdx mice. Lastly, we tested the effect of varying ECC mechanical factors on the level of protection against strength loss by ROS and calcium modulators in isolated EDL muscle using N-acetylcysteine (NAC) and small molecule modulators of SERCA1a and RyR1, respectively. In these experiments, we measured rates of relaxation and Brooks [20] Faulkner/ Chamberlain [21, 22] Davies [23] Duan [24] Gailly [25] Lowe/Ervasti [16, [26] [27] [28] [33] 3 [5] Bath temperature (°C) contraction, in addition to strength loss, in order to gain insight on how the calcium modulators impact physiological outcomes related to fiber calcium kinetics.
Ex vivo muscle preparation
Mice were anesthetized with sodium pentobarbital (75 mg/kg body mass). EDL muscles (15.10 ± 0.12 mg; 13.36 ± 0.04 mm; n = 208) were removed and mounted on a dual-mode muscle lever system (300B-LR; Aurora Scientific Inc.) with 5-0 suture in a 1.2 mL bath assembly filled with oxygenated (95:5% O 2 :CO 2 ) Krebs-Ringer bicarbonate buffer maintained at 25°C. Muscles were adjusted to their anatomical optimal length (L o ) based on resting tension [35] . Muscles remained quiescent in the bath for 5 min before performing maximal isometric tetanic contractions every 2 min. The muscle was stimulated to contract using maximal voltage (150 V) for 200 ms at 175 Hz until force plateaued within 5 mN from one contraction to the next (381 ± 4 mN; 15.80 ± 0.16 N/cm 2 ). Maximal rate of tetanic contraction (+ dP/dt) and relaxation (− dP/dt) were calculated from maximal isometric tetanic force (P o ) and muscle length was measured from myotendinous junction to myotendinous junction using digital calipers.
Force-frequency analysis
Two minutes following plateau of isometric force, a force-frequency analysis was completed. EDL muscles completed 10 isometric contractions (10, 20, 25, 30, 40, 50, 60, 80, 120, 160 Hz) with a 3-min rest between each. Four muscles were used for the force-frequency protocol; they were not used for subsequent ECC protocols.
ECC protocol
Two minutes following plateau of isometric force in separate cohorts of mice, a series of 10 ECC were performed (Additional file 1: Figure S1 ). For each ECC, the muscle was passively shortened 50% of the total length change and then stimulated while the muscle was simultaneously lengthened at a given velocity (see Additional file 1: Figure S1 for specific parameters). Work was calculated from the total force integrated over length change during the first ECC contraction at 120 Hz. Immediately following the 10th ECC, the muscle was readjusted to L o and P o , + dP/dt and -dP/dt were remeasured.
ECC protocol for NAC and calcium flux modulators
Following plateau of isometric force in separate cohorts of mdx mice, EDL muscles (15.95 ± 0.17 mg; 13.66 ± 0.04 mm; 395 ± 7 mN; 15.91 ± 0.28 N/cm 2 ; n = 125) were incubated with NAC (20 mM with the addition of 1% DMSO) or varying concentrations of small molecule SERCA1a activators (DS-11966966 and CDN1163-0.1, 1.0, 10, or 100 μM dissolved in dimethylsulfoxide (DMSO)), small-molecule inhibitors of resting RyR1 leak (Chloroxine and Myricetin-0.01, 0.1, 1.0, 10, or 100 μM dissolved in DMSO), or a combination of molecules. DMSO did not change P o of EDL muscles compared to P o measured during non-DMSO experiments (386 ± 16 vs. 381 ± 4 mN; p = 0.732). After 30 min of incubation where addition of NAC and/or calcium modulator drug also did not affect isometric force production (p ≤ 0.675), P o and + dP/dt and − dP/dt were measured before a series of 10 ECC. For these ECCs, the muscle was passively shortened to 97.5% L o and then stimulated while the muscle was simultaneously lengthened to 102.5% L o , corresponding to a 5% total length change (done at 0.5 L o /s, 200 ms duration). Immediately following the 10th ECC, the muscle was readjusted to L o and P o was measured.
In vivo mouse preparation
Mice were anesthetized with isoflurane and maximal isometric torque (2.84 ± 0.06 mN m; 83.6 ± 2.0 mN m/kg; n = 83) of the anterior crural muscles was measured as previously described [20] . Torque-frequency relationship was then established at varying stimulation frequencies (20, 40, 60, 80, 100, 125, 150, and 200 Hz) with a 45-s rest between each contraction. Eight mice were used for the torque frequency protocol; they were not used for subsequent ECC protocols.
ECC protocol in vivo
One minute after maximal torque was measured, anterior crural muscles were injured by performing 70 electrically stimulated ECC. Stimulation frequencies of 0, 52, 71, 93, and 150 Hz were used to manipulate ECC:ISO, corresponding to passive lengthening or frequencies required to produce 0, 50, 75, 90, or 100% torque between a twitch and tetanus, respectively. Degree of ankle rotation (0, 5, 10, 20, and 40°), contraction velocity (0, 62, 125, 250, 500, 1000, and 2000°/s), and contraction duration (2.5, 5, 10, 20, 40, 80, 160, and 320 ms) were also manipulated to generate a total of 20 protocols. Each ECC was separated by 10 s. Work was calculated from total torque integrated over length change during the first ECC contraction at 150 Hz. Five minutes following the last ECC, isometric tetanic torque was measured.
Evan's blue dye (EBD) assay EBD was diluted in PBS to 5 mg/mL, filter sterilized with a 0.2 μm filter and injected intraperitoneal at 100 μL/10 g body mass 24 h before 15 ECC, as previously described [9] . Fifteen ECC were chosen because it optimally separated torque loss between testing protocols. Twenty-four hours following ECC-induced injury, tibialis anterior muscles were removed, cryopreserved, and later sectioned and stained. Images were acquired on a Leica DM5500 B microscope equipped with a Leica HC PLAN APO × 10 objective and stitched together with LASX software (Leica) to allow visualization of the entire tibialis anterior. MyoVision software (https://www.uky.edu/ chs/muscle/myovision) was used to determine the percentage of EBD-positive fibers in whole tibialis anterior images.
Statistics
Prism 7 software (GraphPad, San Diego, CA) was used for all statistical analyses except those reported in Table 2 , which were computed using JMP (v. 13.1.0 Pro, SAS Institute Inc., Cary NC). For 0 and 35 Hz ex vivo ECC protocols, one-way ANOVA was used to test differences between ECC groups for muscle tension and loss of isometric force compared to initial, and one-way ANOVA with Bonferronized post-hoc tests were used to analyze muscle tension and loss of isometric force when collapsed into length change groups. For the 120 Hz ex vivo ECC protocols, one-way ANOVA was used to test differences between ECC groups for muscle tension and work while a one-way ANOVA with Bonferronized post-hoc tests was used to calculate muscle tension when collapsed into length changes. For ex vivo loss of isometric force, one-way ANOVA with Bonferronized post-hoc tests were used to analyze differences within each length change. When ECC protocols were collapsed into groups by length change, contraction velocity or contraction duration, one-way ANOVA with Bonferronized post-hoc tests were used. Loss of isometric torque and work in vivo between stimulation frequencies and angle rotation was tested using one-way ANOVA with Bonferronized post-hoc tests. A one-way ANOVA with Bonferronized post-hoc tests were used to analyze Evan's blue dye uptake in vivo, changes in isometric and eccentric force between groups when NAC and calcium modulators were added to the ex vivo set-up, and for SERCA activity assays. We compared mechanical factors as single predictors of force loss ex vivo and torque loss in vivo using R 2 for the logarithm of force/torque loss (percent of initial) regressed on each mechanical factor individually. Logarithmic transformation was chosen due to the large variation between and within ECC protocols in loss of isometric force/torque. Data are presented as mean ± SEM with significance set at p < 0.05.
Results
Magnitude of length change and duration of ECC best predict sensitivity to ECC-induced force loss in isolated mdx EDL muscle
We designed ECC protocols within physiological ranges of contractile parameters including length change, velocity, contraction duration, and stimulation frequencies (Additional file 1: Figure S1 ). When EDL muscles were maximally stimulated during ECC (120 Hz), force ( Fig. 1a, b ; p < 0.001), and work ( Fig. 1c, d ; p < 0.001) increased as length change increased. Analyzing the effect of contraction velocity and duration within given length changes showed that ECCs with slower velocities and longer durations resulted in greater loss of isometric force compared to fast and short ECCs (Fig. 1e ). When ECC protocols were grouped by length change, there was a length change-dependent loss of isometric force ( Fig. 1f ; p < 0.001). Grouping ECC protocols by contraction velocity revealed no effect on loss of isometric force ( Fig. 1g ; p = 0.146), but when grouped by duration of the ECC, longer durations resulted in significantly greater force losses down to 94% loss at 600 ms ( Fig. 1h ; p < 0.001). Regression analyses show that the strongest predictor of strength loss was work completed by the muscle during the first ECC, followed by length change, duration, and then ECC:ISO ( Table 2 ). Velocity of the ECC did not predict force loss. Maximal tetanic rates of contraction and relaxation were measured as additional indices of contractile function affected by ECC. Similar to force loss, for a given length change, slower velocities, and longer contraction durations resulted in greater losses of rates of contraction (Additional file 2: Figure  S2A , B) and relaxation (Additional file 2: Figure S2C , D).
To determine if maximal activation of muscle is required, we analyzed the same ECC parameters during submaximal stimulation frequencies of mdx EDL muscles (Additional file 3: Figure S3A ). Following a passive lengthening protocol (0 Hz), isometric force as a percent of initial isometric force differed between protocols (Additional file 4: Figure S4A ; p = 0.012); however, none of the lengthening protocols resulted in loss of force (Additional file 4: Figure S4A In vivo-(isometric torque loss) 0.400 (p < 0.001) 0.542 (p < 0.001) 0.780 (p < 0.001) 0.005 (p = 0.606) 0.311 (p < 0.001) ECC:ISO ratio of maximal eccentric to maximal isometric force Values = coefficient of determination (R 2 ) following 10 and 70 ECC for ex vivo and in vivo contractions, respectively S5A; p < 0.001) with 30% lengthening generating 72% greater eccentric than isometric force (Additional file 5: Figure S5B ; p < 0.001). Similar to the passive lengthening protocol, following the 10th ECC of each, there was a difference in isometric force as a percent of initial between protocols (Additional file 5: Figure S5C ; p < 0.001). When submaximal ECC protocols were assessed by length change, only the 30% group lost isometric force (Additional file 5: Figure S5C , D; p = 0.029) and the loss was minimal (6%) despite the large eccentric force that was generated. Together, these data show that the factors of ECC making mdx EDL muscle sensitive to force loss are the magnitude of lengthening during the contraction and the duration of the ECC but only when stimulation is maximal.
Magnitude of angle change best predicts sensitivity to eccentric torque loss of mdx anterior crural muscles in vivo
To test if the mechanical factors that best predicted force loss ex vivo also had an impact in vivo, we measured strength loss of mdx anterior crural muscles during and following 70 ECC. ECC produced in vivo have similar properties as those ex vivo with the exception that muscle Fig. 1 Mechanical factors that impact the sensitivity of mdx EDL muscle to ECC ex vivo. a Maximal eccentric force as a fraction of maximal isometric tetanic force for each eccentric protocol and b when grouped into length changes. c Work completed during the first contraction of each eccentric protocol and d when grouped into length change. Different from *5%, # 10%, and $ 20%. e Maximal isometric tetanic force (120 Hz) following 10 eccentric contractions as a percent of maximal isometric force before ECC (initial). Different from the *first, # second, and $ third protocol within a given length change. f Isometric tetanic force as a percent of initial for each protocol when collapsed into length changes and g velocities. Different from *5%, # 10%, and $ 20%. h Isometric tetanic force as a percent of initial for each protocol when grouped into contraction durations. L o , optimal muscle length. Different from *25 ms, # 50 ms, $ 66 ms, and + 100 ms. Data are mean ± S.E.M with significance set at p < 0.05. N = 5-6/protocol lengthening occurs by rotation about a joint, here ankle plantarflexion, reported as angle change with velocity in degree/s and strength being measured as torque. As expected, isometric and ECC:ISO torques increased with increasing stimulation frequency (Additional file 3: Figure  S3B and Fig. 2a ), and there was loss of isometric torque following 70 ECCs only at the highest frequencies (Fig. 2b,  c ; p < 0.001). Because length change was a strong predictor of isometric force loss in isolated EDL muscle (Table 2) , we then manipulated ECC:ISO by changing the degree of ankle rotation, the in vivo equivalent of muscle length change. ECC:ISO of the anterior crural muscles increased with angle change (Fig. 2d ; p < 0.001) which resulted in a greater loss of eccentric and isometric torque following 70 ECCs ( Fig. 2e, f; p < 0.001) . Contraction velocity and duration were manipulated next. Each condition elicited high ECC:ISO torque with only the fastest velocity and shortest duration being different ( Fig. 2g ; p = 0.022). Interestingly, this slightly higher ECC:ISO combination resulted in substantially less eccentric torque loss ( Fig. 2h ; p < 0.001) but no difference in loss of isometric torque ( Fig. 2i ; p = 0.075). When the angle change was reduced to 10°, relatively low ECC:ISO torques yielded similar torque losses ( Fig.  2j-l ; p < 0.001). Because work was the strongest predictor of isometric force loss in isolated EDL muscle ( Table 2 ), we measured work in all in vivo protocols at 150 Hz and determined a greater change in ankle rotation resulted in more work (Additional file 6: Figure  S6A , B; p < 0.001). Overall, the data indicate that the degree of ankle rotation, and therefore, the change in muscle length, tunes the sensitivity of mdx anterior crural muscles to ECC in vivo. This conclusion was substantiated by regression analyses showing that ECCinduced torque loss was strongly predicted by angle/ length change (Table 2) . Work completed during the first ECC, followed by stimulation duration and ECC: ISO also significantly predicted torque loss while contraction velocity did not. These data are similar to the ex vivo results except that work was the strongest predictor in isolated EDL muscle.
Sarcolemmal damage is associated with the muscle length change of an eccentric contraction in vivo
Sarcolemmal damage of mdx skeletal muscle positively correlates with ECC ex vivo [5] and in vivo [9] . To determine whether the level of muscle damage is associated with mechanical factors of an ECC, we measured EBD uptake in mdx tibialis anterior muscles exposed to three ECC protocols in vivo that varied by angle change and stimulation frequency. There was an angle changedependent increase in EBD-positive fibers while passive rotation did not differ in EBD-positive fibers from the contralateral muscle (Fig. 3) . These data indicate that the magnitude of ankle rotation and therefore, the change in tibialis anterior muscle length impacts sarcolemmal damage in mdx muscle exposed to ECC resulting in up to 21% of the fibers being positive for EBD.
The antioxidant NAC protects mdx muscle from ECCinduced force loss in a muscle length change-dependent manner
ECC-induced force loss of isolated mdx EDL muscle is associated with oxidative stress [9, 36] . We have previously shown that addition of NAC partially protects mdx EDL muscle from losing force from ECCs of a 10% length change [9] , and here we confirmed this result (Fig. 4a, b ). Because length change strongly tunes the sensitivity of mdx EDL muscle to ECC (Fig. 1) , we posited that modulations in force loss caused by varying the length change would be related to oxidative stress. When length change was reduced to 5%, the force loss between ECC 2-8 was reduced relative to that at 10%, and the addition of NAC provided more substantial protection ( Fig. 4c, d ) compared to 10% length change (Fig.  4a, b) . These data indicate that the magnitude of length 
Small-molecule calcium modulators protect mdx muscle from ECC-induced force loss in a length changedependent manner
Changes in cytosolic calcium have been implicated in ECC-induced force loss of mdx muscle [11, 12, 37] , and increasing SERCA1a activity or reducing RyR1 SR leak have been shown to ameliorate several dystrophic phenotypes [12, [37] [38] [39] [40] . Here, we incubated mdx EDL muscles with small-molecule calcium modulators that were previously identified through high-throughput screening assays as activators of SERCA (DS-11966966 and CDN1163; Additional file 7: Figure S7 , [41] [42] [43] [44] ) or inhibitors of RyR1 leak (Chloroxine and Myricetin, [45] ). After demonstrating that these calcium modulators affected contraction kinetics, particularly relaxation (Additional file 8 Figure S8 and Additional file 9: Figure  S9 ), we tested four concentrations of each modulator (Additional file 10: Figure S10 ) and measured significant attenuation of ECC-induced force loss (Fig. 5a, b) . The effects of the best performing SERCA1a activator (CDN1163) and RyR1 inhibitor (Myricetin) were additive in providing greater protection against ECC-induced force loss than either agent alone (Fig. 5c, d) . To further examine the effect of modulating both calcium and oxidative stress, we incubated mdx EDL muscle with CDN1163 + Myricetin + NAC and measured an even greater protection from ECC-induced force loss sparing 50% of ECC force at contraction 10 (Fig. 5d ). However, isometric force following the 10th contraction was not different between CDN1163 + Myricetin + NAC and NAC alone (Fig. 5d ). Because NAC provided the greatest protection from strength loss, we measured maximal rates of contraction and relaxation and determined that NAC improves both (Fig. 5e, f ), suggesting that scavenging of ROS impacts RyR1 and SERCA1a activity in isolated mdx EDL muscle.
Discussion
Sensitivity to ECC has become a hallmark of dystrophindeficient skeletal muscle in animal models of DMD since its first report [5] . Even though research using DMD mouse models routinely utilizes ECC as a robust phenotype to test the efficacy of genetic and pharmacological interventions, the reason why this specific type of contraction causes strength loss is not clear. Here, we aimed to identify which mechanical component of an ECC initiates ECC-induced strength loss in mdx mice. We found that the magnitude of work, length change, and stimulation duration of an ECC are all strong predictors of strength loss and that a high stimulation frequency to elicit near-maximal strength generation is required. These mechanical factors of an ECC explain why the magnitude of strength loss in mdx muscle varies so (Table 1) . We utilized this new knowledge in mdx mouse muscle to optimize parameters of our ECC protocol in order to effect significantly greater protection against force loss by a ROS scavenger and small-molecule calcium modulators.
The magnitude of muscle length change ex vivo, or degree of ankle rotation in vivo, were dominant factors sensitizing mdx muscle to ECC-induced strength loss, indicating that a major component of sensitivity is associated with the degree of stretch imposed on the muscle during contraction, and this is similar to WT muscle [14, 46] . The amount of work completed during the first ECC, which is directly proportional to length change, was an equally strong predictor of ECC-induced strength loss and similar to previous reports in WT muscle as well [13] . The duration of the contraction was also associated with, and predictive of, the sensitivity of mdx muscle to ECC (Table 2) . Interestingly, ECC:ISO were less predictive and contraction velocity was not predictive, which differs from dystrophin-containing WT muscle [15, 47, 48] . Collectively, mechanical factors of a contraction impact the sensitivity of mdx muscle to ECC similarly in ex vivo and in vivo muscle preparations.
There are multiple ECC protocols used to differentiate WT skeletal muscle from dystrophin-deficient skeletal muscle, as well as testing the efficacy of various genetic therapies and pharmacological interventions for DMD (e.g., Table 1 ). With such disparity in total length change A novel finding of this study is that dystrophindeficient skeletal muscle was only sensitive to ECC when near-maximal muscle fiber activation was achieved through a high stimulation frequency. There was no loss of strength when mdx muscle was mechanically lengthened without stimulation (i.e., passively stretched within anatomical limits) (Additional file 4: Figure S4 and 2C) and when submaximal stimulation frequencies were used for ECCs ex vivo or in vivo, regardless of the eccentric force or torque generated, minimal strength was lost (Additional file 5: Figure  S5 and 2C). This finding could be interpreted as dystrophin-deficient skeletal muscle actually being quite resilient to ECC, as maximal muscle activation rarely occurs with voluntary movements in vivo. It is important to keep in mind that skeletal muscle of mdx mice does not completely recapitulate the human DMD phenotype, particularly with regard to pathology, and may contribute to the need of maximal ECC to induce strength loss. Thus, while submaximal stimulation may not induce force or torque loss in mdx mice, submaximal ECCs may affect patients with dystrophin deficiency. To our knowledge, there have not been clinical investigations that have subjected patients with DMD to ECC. Our results may offer researchers a foundation for examining exercise paradigms that include both submaximal concentric and eccentric contractions in patients with DMD.
ECC strength loss of mdx muscle was originally thought to be caused by muscle damage [5] , which would agree with our new data indicating that mechanical parameters of an ECC impact the extent of sarcolemmal permeability (Fig. 3 ). However, there is a well-documented disconnect [5] between the amount of damage and force loss following ECCs in mdx muscle, as is seen in this study with damage measured by EBD-positive fibers (21%) not matching with the degree of total strength loss (70%). EBD staining in dystrophin-deficient mouse muscle associates with IgG, IgM, and albumin staining [49] further indicating sarcolemmal damage-although the extent that membrane lesions smaller than those allowing infiltration of such molecules contribute to strength loss is not clear. Nonetheless, these results lead us to propose that the majority of strength loss in mdx muscle exposed to ECC is not merely the result of damage to the sarcolemma, but rather a complex, multi-factorial insult that involves oxidative stress and cytosolic calcium disruption, which culminates in fiber depolarization and inexcitability [17, 18] . Furthermore, we propose that the various factors involved can be modulated to produce a graded sensitivity of mdx muscle to strength loss by (1) altering mechanical parameters of an ECC, such as shortening the ECC length change from 10 to 5% and (2) directly altering calcium kinetics (SERCA1a and RyR1 small molecule modulators) or redox balance within the muscle. This idea is supported by measuring a greater protection with NAC at 5% compared to a 10% length change, which we hypothesize is due to variable levels of mechanically induced oxidative stress and by previous work highlighting that protection from ECC-induced strength loss of mdx muscle can be achieved with (a) antioxidants [9, 10] , similar to our current results with NAC ( Fig. 4) ; (b) blocking stretch-activated calcium channels [7] ; or (c) inhibition of RyR1 leak [12] , comparable to our results with Chloroxine and Myricetin (Fig. 5 ). Adding to the list, ours is the first study to demonstrate the benefit of pharmacologically increasing SERCA activity in protecting mdx muscle from ECC strength loss, similar to that accomplished by SERCA1a overexpression [11] .
Conclusions
Our results demonstrate that mdx muscle becomes sensitized to ECC based on the magnitude of work, length change, and stimulation duration of the ECC, with a high stimulation frequency also being required. We posit that it is essential, when testing an intervention in dystrophin-deficient skeletal muscle using ECC, that an understanding of the ECC protocol parameters and predicted outcome is judiciously applied. Here, we show how such awareness can be utilized for testing an antioxidant and calcium modulators as potential DMD therapeutics, demonstrating a complex interplay of biological factors underlying strength loss in mdx muscle.
